News facts:
- ams and Senova successfully opened a production line for lateral flow based test kits which will be used to detect antibodies from the Covid-19 (SARS-CoV-2) virus
- From idea to production in under nine months: production starts for highly sensitive quantitative lateral flow rapid tests to fight Covid-19 (SARS-CoV-2) pandemic
- The Senova GreenLight platform process the data in a secure medical cloud and
- The ams AS7341L allows spectrally resolved accurate read-out of lateral flow immune assays
- The cost-effective platform is applicable in doctor’s office and other point of care situations
Click
here for online version.